US 11,891,614 B2
Methods for engineering allogeneic and immunosuppressive resistant T cell for immunotherapy
Roman Galetto, Paris (FR); Agnes Gouble, Paris (FR); Stephanie Grosse, Saint-cyr sur Morin (FR); Cecile Mannioui, Villiers sur Marne (FR); Laurent Poirot, Paris (FR); Andrew Scharenberg, Seattle, WA (US); and Julianne Smith, Le Plessis-Robinson (FR)
Assigned to CELLECTIS, Paris (FR)
Filed by Cellectis, Paris (FR)
Filed on May 17, 2020, as Appl. No. 16/876,079.
Application 16/876,079 is a continuation of application No. 16/027,629, filed on Jul. 5, 2018, abandoned.
Application 16/027,629 is a continuation of application No. 13/892,805, filed on May 13, 2013, granted, now 11,603,539.
Claims priority of provisional application 61/696,612, filed on Sep. 4, 2012.
Claims priority of provisional application 61/651,933, filed on May 25, 2012.
Prior Publication US 2020/0281979 A1, Sep. 10, 2020
Int. Cl. C12N 15/87 (2006.01); C07H 21/04 (2006.01); C12N 15/85 (2006.01); A61K 35/17 (2015.01); C07K 14/705 (2006.01); C12N 5/0783 (2010.01); C07K 14/725 (2006.01); C07K 16/28 (2006.01); A01K 67/00 (2006.01); A61K 39/00 (2006.01); A61K 38/00 (2006.01)
CPC C12N 15/85 (2013.01) [A61K 35/17 (2013.01); C07K 14/7051 (2013.01); C07K 14/70517 (2013.01); C07K 14/70521 (2013.01); C07K 14/70578 (2013.01); C07K 16/28 (2013.01); C07K 16/2803 (2013.01); C12N 5/0636 (2013.01); A61K 38/00 (2013.01); A61K 39/00 (2013.01); C07K 2317/14 (2013.01); C07K 2317/24 (2013.01); C07K 2317/569 (2013.01); C07K 2317/622 (2013.01); C07K 2319/00 (2013.01); C07K 2319/03 (2013.01); C07K 2319/74 (2013.01); C12N 2501/39 (2013.01); C12N 2501/51 (2013.01); C12N 2501/515 (2013.01); C12N 2501/599 (2013.01); C12N 2502/99 (2013.01); C12N 2510/00 (2013.01)] 16 Claims
 
1. A method of preparing engineered T-cells for immunotherapy comprising
(a) inactivating PDCD1 in the T-cells comprising introducing into the T-cells by electroporation of RNAs encoding at least two half Transcription activator-like effector nucleases (TALE-nucleases) able to selectively inactivate by DNA cleavage a gene encoding PDCD1, to produce engineered T-cells; and
(b) expanding said engineered T-cells,
wherein said at least two half TALE-nucleases recognize and cleave a target sequence selected from SEQ ID NO:77 and SEQ ID NO:78;
wherein introducing said at least two half Transcription activator-like effector nucleases (TALE-nucleases) into said T-cells comprises contacting said engineered T-cells with RNAs encoding said at least two half TALE-nucleases; and
i. applying an agile pulse sequence consisting of: one electrical pulse with a voltage range from 2250 to 3000 V per centimeter, a pulse width of 0.1 ms and a pulse interval of 0.2 to 10 ms between the electrical pulses of steps (i) and (ii);
ii. one electrical pulse with a voltage range from 2250 to 3000 V with a pulse width of 100 ms and a pulse interval of 100 ms between the electrical pulse of step (ii) and the first electrical pulse of step (iii); and
iii. 4 electrical pulses with a voltage of 325 V with a pulse width of 0.2 ms and a pulse interval of 2 ms between each of 4 electrical pulses.